Passage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance

Reuters11-11

<a href="https://laohu8.com/S/PASG">Passage Bio</a> reports Q3 net loss of $7.7 million on $52.8 million cash balance

Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571642-en) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582800743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582800743","market":"us","top_or_hot":-1,"title":"Passage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PASG\">Passage Bio</a> reports Q3 net loss of $7.7 million on $52.8 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571642-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Passage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPassage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PASG\">Passage Bio</a> reports Q3 net loss of $7.7 million on $52.8 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571642-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PASG","symbol_name":"Passage Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9TfJCV:1","article_id":"2582800743","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582800743","pubTimestamp":1762809319,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PASG":"Passage Bio, Inc.","BK4139":"生物科技"},"translate_title":"Passage Bio报告第三季度净亏损770万美元，现金余额为5280万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PASG":0.9},"content_text":"Passage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance\n    \n\n        Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571642-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582800743","isCrawlerRequest":true}